| Segment Reporting Disclosure [Text Block] |
In accordance with FASB ASC 280, “Segment Reporting,” the Company discloses financial and descriptive information about its reportable segments. The Company operates in two segments, iBio, Inc. and iBio CDMO. Management has determined that the activity of iBio CDMO should be segregated as a separate segment and that the activity of iBio Brazil is currently immaterial and is to be included in the activity of iBio, Inc. These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. | Three Months Ended September 30, 2017 (in thousands) | | iBio, Inc. | | iBio CDMO | | Eliminations | | Total | | | | | | | | | | | | | | | | | | Revenues - external customers | | $ | 84 | | $ | 38 | | $ | - | | $ | 122 | | | Revenues – intersegment | | | 301 | | | 210 | | | (511) | | | - | | | Research and development | | | 618 | | | 484 | | | (117) | | | 985 | | | General and administrative | | | 1,099 | | | 1,698 | | | (299) | | | 2,498 | | | Operating loss | | | (1,332) | | | (2,029) | | | - | | | (3,361) | | | Interest expense | | | - | | | (480) | | | - | | | (480) | | | Interest and other income | | | 12 | | | 2 | | | - | | | 14 | | | Consolidated net loss | | | (1,321) | | | (2,506) | | | - | | | (3,827) | | | Total assets | | | 18,810 | | | 27,485 | | | (12,862) | | | 33,433 | | | Fixed assets, net | | | 7 | | | 25,261 | | | - | | | 25,268 | | | Intangible assets, net | | | 1,757 | | | - | | | - | | | 1,757 | | | Depreciation expense | | | 1 | | | 337 | | | - | | | 338 | | | Amortization of intangible assets | | | 85 | | | - | | | - | | | 85 | | | Three Months Ended September 30, 2016 (in thousands) | | iBio, Inc. | | iBio CDMO | | Eliminations | | Total | | | | | | | | | | | | | | | | | | Revenues - external customers | | $ | 86 | | $ | 49 | | $ | - | | $ | 135 | | | Revenues – intersegment | | | 152 | | | 182 | | | (334) | | | - | | | Research and development | | | 684 | | | 321 | | | (185) | | | 820 | | | General and administrative | | | 1,347 | | | 1,271 | | | (149) | | | 2,469 | | | Operating loss | | | (1,793) | | | (1,361) | | | - | | | (3,154) | | | Interest expense | | | - | | | (483) | | | - | | | (483) | | | Interest and other income | | | 18 | | | 7 | | | - | | | 25 | | | Consolidated net loss | | | (1,775) | | | (1,837) | | | - | | | (3,612) | | | Total assets | | | 11,810 | | | 36,330 | | | (49) | | | 48,091 | | | Fixed assets, net | | | 8 | | | 25,572 | | | - | | | 25,580 | | | Intangible assets, net | | | 2,023 | | | - | | | - | | | 2,023 | | | Depreciation expense | | | 1 | | | 323 | | | - | | | 324 | | | Amortization of intangible assets | | | 88 | | | - | | | - | | | 88 | |
|